- HCV+ kidneys can be safely transplanted into HCV+ recipients, with subsequent viral eradication by direct-acting antiviral (DAA) therapy.
Why this matters
- Authors note that growing US opioid epidemic has led to a surge in available HCV+ organs over the past several years.
- Use of HCV+ organs can reduce waitlist times and expand the donor pool, with positive effects on survival.
- Single-center retrospective review of 12 HCV-infected patients (mean age, 63.7 years) who received viremic kidneys and were subsequently treated with ribavirin (RBV)-free ledipasvir/sofosbuvir (LDV/SOF).
- 2 patients received combined liver/kidney transplant.
- All received induction immunosuppression with methylprednisolone, followed by prednisone taper and mycophenolate mofetil (MMF); tacrolimus was started shortly after transplant.
- Funding: None.
- 75% of patients had HCV-1a infection, and 58.3% were treatment-naive; none had previously received DAAs or had cirrhosis.
- All had estimated glomerular filtration rate >40 mL/minute/1.73 m2, maintained after treatment.
- Median waitlist time, 74 days.
- Median time from transplant to DAA initiation, 119 days.
- 83.3% were treated for 12 weeks; 16.7% received a 24-week regimen.
- All achieved sustained virologic response at 12 weeks posttherapy (SVR12).
- No tacrolimus discontinuations or graft rejection occurred.
- 1 patient required MMF discontinuation for neutropenia.
- Sample size.